Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Deferoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | KDM4A | O75164 | 11/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.88 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.88 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.88 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferoxamine SCHEMBL3953046 | 0.99 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL7715593 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1699778 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL119982 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL30036991 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9351925 | 0.96 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1034134 | 0.95 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1509901 | 0.95 | KDM4A (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL3115584 | 0.95 | KDM4A (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9555338 | 0.94 | KDM4E (0.93) | KDM4ELMNAGAASMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385933-B1 | CULTURE MEDIUM FOR CELL GROWTH AND TRANSFECTION | LIFE TECHNOLOGIES CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2351827-A1 | Culture medium for cell growth and transfection | Life Technologies Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183375-A1 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS | Life Technologies Corporation (US) | 2011-07-28 | — | — | US | disclosed |
| US-20080286868-A1 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS | INVITROGEN CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-6767741-B1 | THE COMPOSITIONS OBVIATE THE NEED FOR NATURALLY DERIVED METAL-BINDING PROTEINS, SUCH AS TRANSFERRIN AND CERULOPLASMIN, WHICH MAY CONTAIN BLOOD-BORNE PATHOGENS | INVITROGEN CORPORATION | 2004-07-27 | — | — | US | disclosed |